AI-generated · cited to primary sources · not investment advice
Apollo Hospitals (508869) Nov 2025 Filing Analysis
Does management do what it says?
The composite scheme involving the amalgamation of Keimed and the restructuring of the pharmacy business is underway to achieve the 100% ownership structure. (1 in progress across 1 tracked commitment)
“Continue to evaluate bolt-on acquisitions in select Tier -1 cities & Metros”
The company expects EBITDA losses from the six new hospitals to be approximately INR 150 crore in the next fiscal year. — target: INR 150 crore (+1 more commitment)
“We continue to believe that next year, overall EBITDA losses from these hospitals should be around the INR 150 crore number, which is what would be the EBITDA losses from these hospitals”
The internal target for hospital business EBITDA margins is to increase them by 500 basis points from the current base. — target: 500 basis points increase
“And clearly, we would, the internal target is to take it higher by 500 basis points.”
Management targets a 30% organic growth trajectory for the hospital business, supported by the recovery of the Bangladesh market and expansion into new international territories. — target: 30%
“Yes. I think we are quite confident that we will get back into 30%. We say this because Bangladesh, at least 60% has started coming back in October and we believe that we will mitigate the impact of losing one territory. Also, we are exploring new markets, including the Northern markets in Uzbekistan, etcetera.”
See the full cited Management analysis of Apollo Hospitals
How durable is the business?
Average Length of Stay (ALOS) dropped by 7% due to the adoption of new technologies like robotics and digital command centers, which improves bed turnover and efficiency. (1 expanding)
“ALOS has dropped by 7%... the use of new technologies, whether it is the cardiac where we have minimally resistant or robotics. So, this is really driving down ALOS and allowing us to discharge patients much faster.”
See the full cited Business Model analysis of Apollo Hospitals
Where does growth come from?
ARPP is accelerating, showing a 9% YoY growth in Q2 FY26 compared to the previous year, driven by a 14% increase in revenue from high-complexity 'CONGO' specialties. (1 accelerating, 1 steady across 2 signals)
“Average Revenue per In patient grew by 9% to ₹ 173,318 in Q2FY26... partly offset by 14% increase in Revenue from CONGO Specialties.”
See the full cited Future Growth analysis of Apollo Hospitals
What could break the thesis?
The risk is easing as management reports that international patients from Bangladesh (a key driver for Northern/Metro hubs) began returning in October, and they are diversifying into new markets like Uzbekistan and Africa. (1 easing)
“Bangladesh, at least 60% has started coming back in October and we believe that we will mitigate the impact of losing one territory. Also, we are exploring new markets, including the Northern markets in Uzbekistan, etcetera.”
See the full cited Risk analysis of Apollo Hospitals
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.